ARHGEF12 mutations were initially identified in acute myeloid leukemia and B-cell lymphoma, KMT2A-ARHGEF12 fusion caused hematologic disorders and associated with poor prognosis 22-24. This evidence concerns the gene ARHGEF12 and B-cell non-Hodgkin lymphoma.